論文 - 詳細
| RRC ID | 64619 |
|---|---|
| 著者 | Kunishige I, Samejima Y, Shiki Y, Moriyama A, Meruelo D, Saji F, Murata Y. |
| タイトル | Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase. |
| ジャーナル | Gynecol Oncol |
| Abstract |
In gene therapy, the herpes simplex virus thymidine kinase (HSV-tk) gene is widely used as a suicide agent. Tumor cells expressing HSV-tk are sensitive to nucleoside analogs such as ganciclovir (GCV). An advantage of this system is the bystander killing effect whereby HSV-tk-positive cells exposed to GCV are lethal to surrounding HSV-tk-negative cells. We transfected the HSV-tk gene into a human cervical adenocarcinoma cell line, BU25TK-, and a human endometrial adenocarcinoma cell line, HHUA, by the Lipofectine method. The sensitivity of HSV-tk-positive cells to GCV and bystander killing effect on HSV-tk-negative cells were examined in vitro. HSV-tk-positive cells were sensitive to GCV at concentrations of 1 to 100 microg/ml in a dose- and time-dependent manner. The growth of HSV-tk-negative cells was inhibited when the population of cultured cells contained more than about 3% HSV-tk-positive cells. Moreover, for BU25TK- cells, HSV-tk-positive cells were injected into SCID mice subcutaneously and the effects of GCV therapy and bystander killing at a daily concentration of 25 mg/kg for 14 days were examined. HSV-tk-positive tumors transduced into SCID mice almost disappeared upon GCV treatment. Furthermore, tumor reduction was observed when mixtures of HSV-tk-negative cells containing more than 20% HSV-tk-positive cells were injected into SCID mice. In conclusion, the HSV-tk/GCV system might be applied to both cervical and endometrial adenocarcinoma. |
| 巻・号 | 72(1) |
| ページ | 16-25 |
| 公開日 | 1999-1-1 |
| DOI | 10.1006/gyno.1998.5224 |
| PII | S0090-8258(98)95224-6 |
| PMID | 9889024 |
| MeSH | Adenocarcinoma / genetics Adenocarcinoma / therapy* Animals Female Ganciclovir / therapeutic use Genetic Therapy / methods* Humans Mice Mice, SCID Simplexvirus* / genetics Thymidine Kinase* / genetics Tumor Cells, Cultured Uterine Neoplasms / genetics Uterine Neoplasms / therapy* |
| IF | 4.623 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 2 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HHUA(RCB0658) BU25 TK-(RCB0205) |